Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b9036c33bbe3f4ea428655b76200f7c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-72 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
filingDate |
2006-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c69fdb6e5eadb79195d3e00d87da2eb8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c98aaebebfc912853930a97d7a13ff23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c77936fce552d2606835f91c46d9f71 |
publicationDate |
2008-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-1921090-A1 |
titleOfInvention |
Genetically modified antibody composition |
abstract |
The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11680104-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9556279-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2543727-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2543727-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10040861-B2 |
priorityDate |
2005-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |